Jiangsu Aosaikang Pharmaceutical Co., Ltd. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Nanjing China (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2017
NCT03011125
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Jiangsu Aosaikang Biomedicine Co. LTD. | Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 11